hiv associated lipodystrophy syndrome

Summary

Summary: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.

Top Publications

  1. ncbi HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy
    Nicolas Dupin
    Service de Dermatologie CRPI, Universite Rene Descartes, Paris V, Hopital Tarnier Cochin, 89 rue d Assas, 75006 Paris, France
    AIDS 16:2419-24. 2002
  2. ncbi Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial
    Veronique Joly
    Service de Maladies Infectieuses et Tropicales A, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, Paris, France
    AIDS 16:2447-54. 2002
  3. ncbi Current perspectives on HIV-associated lipodystrophy syndrome
    Ana Milinkovic
    Clinical Institute of Infections and Immunology, Institu d Investigacions Biomédiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    J Antimicrob Chemother 56:6-9. 2005
  4. ncbi Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    Steven Grinspoon
    Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 352:48-62. 2005
  5. ncbi HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
    Andrew Carr
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS 17:S141-8. 2003
  6. ncbi Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution
    N R Reynolds
    Ohio State University College of Nursing and AIDS Clinical Trials Unit, Columbus, OH 43210, USA
    AIDS Care 18:663-73. 2006
  7. ncbi Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients
    P Mercie
    Internal Medicine and Infectious Diseases, University Hospital of Bordeaux, France
    HIV Med 6:380-7. 2005
  8. ncbi The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults
    Robert Burgoyne
    Toronto General Hospital Immunodeficiency Clinic, Ontario, Canada
    Qual Life Res 14:981-90. 2005
  9. ncbi A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy
    G J Moyle
    Chelsen and Westminster Hospital, London, Uned Kingdom
    J Acquir Immune Defic Syndr 33:22-8. 2003
  10. ncbi Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study
    Allison Martin
    National Centree in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 18:1029-36. 2004

Detail Information

Publications205 found, 100 shown here

  1. ncbi HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy
    Nicolas Dupin
    Service de Dermatologie CRPI, Universite Rene Descartes, Paris V, Hopital Tarnier Cochin, 89 rue d Assas, 75006 Paris, France
    AIDS 16:2419-24. 2002
    ..To determine HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy...
  2. ncbi Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial
    Veronique Joly
    Service de Maladies Infectieuses et Tropicales A, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, Paris, France
    AIDS 16:2447-54. 2002
    ..To compare the incidence of clinical lipodystrophy in HIV-1-infected patients receiving zidovudine or stavudine, in combination with indinavir and lamivudine, in a randomized trial...
  3. ncbi Current perspectives on HIV-associated lipodystrophy syndrome
    Ana Milinkovic
    Clinical Institute of Infections and Immunology, Institu d Investigacions Biomédiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    J Antimicrob Chemother 56:6-9. 2005
    ..The issue of body composition has become extremely important for the adequate management of HIV-infected patients...
  4. ncbi Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    Steven Grinspoon
    Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 352:48-62. 2005
  5. ncbi HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
    Andrew Carr
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS 17:S141-8. 2003
    ..A variety of therapeutic interventions, designed to limit these risks, are under evaluation, but none is conclusively shown to be of value...
  6. ncbi Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution
    N R Reynolds
    Ohio State University College of Nursing and AIDS Clinical Trials Unit, Columbus, OH 43210, USA
    AIDS Care 18:663-73. 2006
    ....
  7. ncbi Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients
    P Mercie
    Internal Medicine and Infectious Diseases, University Hospital of Bordeaux, France
    HIV Med 6:380-7. 2005
    ..In a 12-month follow-up study, we aimed to investigate changes in carotid intima-media thickness (IMT), a surrogate marker of atherosclerosis, and its determinants in HIV-1-infected patients...
  8. ncbi The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults
    Robert Burgoyne
    Toronto General Hospital Immunodeficiency Clinic, Ontario, Canada
    Qual Life Res 14:981-90. 2005
    ..To investigate the relationship between lipodystrophy-specific symptom severity and wellbeing...
  9. ncbi A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy
    G J Moyle
    Chelsen and Westminster Hospital, London, Uned Kingdom
    J Acquir Immune Defic Syndr 33:22-8. 2003
    ..The mechanisms by which dyslipidemia and lipoatrophy develop during antiretroviral therapy are not clear. No treatment of lipoatrophy is currently established...
  10. ncbi Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study
    Allison Martin
    National Centree in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 18:1029-36. 2004
    ..To determine if long-term improvement in HIV lipoatrophy can be attained by substitution of thymidine analogues zidovudine (ZDV) or stavudine (d4T) with abacavir (ABC)...
  11. ncbi Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability
    Stacey L Silvers
    Chelsea Eye and Cosmetic Surgery Associates, New York, NY 10011, USA
    Plast Reconstr Surg 118:34S-45S. 2006
    ..The objective was to evaluate the safety and effectiveness of soft-tissue augmentation of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary to human immunodeficiency virus disease...
  12. ncbi A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS 20:2043-50. 2006
    ..Peripheral fat loss, lipoatrophy, appears most associated with prolonged therapy with thymidine nucleoside analogues...
  13. ncbi Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    AIDS 17:1329-38. 2003
    ..Adipose tissue morphology was also assessed...
  14. ncbi Long-term complications of antiretroviral therapy: lipoatrophy
    L Waters
    Chelsea and Westminster Hospital, Department of HIV GU Medicine, London, UK
    Int J Clin Pract 61:999-1014. 2007
    ..Ultimately, prevention of this condition is the best approach by avoiding thymidine analogues wherever possible or careful monitoring with early switching away from these agents. New therapies to treat pre-existing fat loss are required...
  15. ncbi Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study
    Jussi Sutinen
    Department of Medicine, Division of Diabetes, Helsinki University Central Hospital, Helsinki, Finland
    Antivir Ther 8:199-207. 2003
    ..Rosiglitazone unexpectedly caused significant increases in serum triglyceride and cholesterol concentrations, which must be carefully monitored if glitazones are used in these patients...
  16. ncbi Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial
    Colleen Hadigan
    Massachusetts General Hospital and Brigham and Women s Hospital, Boston, Massachusetts 02114, USA
    Ann Intern Med 140:786-94. 2004
    ....
  17. ncbi Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors
    Claudia Paula Santos
    Casa da AIDS, Hospital das Clinicas, School of Medicine, University of Sao Paulo, Brazil
    AIDS 19:S14-21. 2005
    ..This study analyses patients' self-perception of central fat gain (CFG) and peripheral fat loss (PFL)...
  18. pmc A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals
    R Power
    Royal Free and University College Medical School, London, UK
    Sex Transm Infect 79:137-41. 2003
    ..To investigate the psychosocial impact of lipodystrophy on the lifestyles of HIV positive patients on highly active antiretroviral therapy (HAART)...
  19. ncbi No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Andrew Carr
    St Vincent s Hospital, Sydney, Australia
    Lancet 363:429-38. 2004
    ..We postulated that rosiglitazone would improve HIV lipoatrophy...
  20. ncbi Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
    ..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy...
  21. ncbi Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)
    Laurence Slama
    Department of Infectious and Tropical Diseases, Tenon Hospital, Paris, F 75020 France
    Antivir Ther 13:67-76. 2008
    ..Although thiazolidinediones have been shown to increase subcutaneous fat in congenital lipodystrophy, rosiglitazone did not show convincing results in HIV lipoatrophy. We assess a potential specific effect of pioglitazone in this setting...
  22. ncbi Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors
    Esteban Martinez
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Antivir Ther 8:403-10. 2003
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  23. ncbi A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy
    Rodrigo B Cavalcanti
    Department of Medicine and McLaughlin Rotman Centre, University Health Network, Toronto, ON, M5T 2S8, Canada
    J Infect Dis 195:1754-61. 2007
    ..Thiazolidinediones such as rosiglitazone may have benefit in ameliorating human immunodeficiency virus (HIV) lipoatrophy...
  24. ncbi Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy
    Rajagopal V Sekhar
    Division of Endocrinology, Baylor College of Medicine, 719E, One Baylor Plaza, Houston, TX 77030, USA
    Curr Atheroscler Rep 6:173-9. 2004
    ..In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease...
  25. ncbi Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review
    Birgitte R Hansen
    Department of Infectious Diseases, Hvidovre University Hospital, Denmark
    Scand J Infect Dis 36:244-53. 2004
    ..highly active antiretroviral therapy (HAART), metabolic and morphological complications known as HIV associated lipodystrophy syndrome (HALS) have been increasingly common...
  26. ncbi Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients
    P F Grima
    Operative Unit of Infectious Diseases, S Caterina Novella s Hospital, Via Roma 1, 73013, Galatina, Lecce, Italy
    Radiol Med 114:141-51. 2009
    ..We performed a cross-sectional study of physical changes in HIV-infected adults to evaluate the role of ultrasonography for the diagnosis of lipodystrophy...
  27. ncbi Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy
    Massimo Galli
    Institute of Infectious Diseases and Tropical Medicine, L Sacco Hospital, University of Milan, Milan, Italy
    Antivir Ther 8:347-54. 2003
    ..To assess the correlates of risk of the different types of lipodystrophy and their modifications over time in a cohort of HIV-positive women receiving antiretroviral therapy (ART)...
  28. ncbi HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy
    E Fliers
    Department of Endocrinology and Metabolism, Academic Medical Centre of the University of Amsterdam, 1105 AZ, Amsterdam, Netherlands
    Lancet 362:1758-60. 2003
    ..We propose that HARS is mediated by effects of antiretroviral treatment on the CNS and could indicate a change in autonomic balance resulting in redistribution of adipose tissue...
  29. ncbi A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy
    R Kohli
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Department of Public Health and Family Medicine, Tufts University School of Medicine, Boston, MA 02111, USA
    HIV Med 8:420-6. 2007
    ....
  30. ncbi HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies
    Polyxeni Koutkia
    Massachusetts General Hospital Program in Nutritional Metabolism and Neuroendocrine Unit, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Annu Rev Med 55:303-17. 2004
    ..However, the long-term effects on cardiovascular disease have not yet been determined...
  31. ncbi Pharmacologic therapy for HIV-associated lipodystrophy
    Sandra Benavides
    College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Ann Pharmacother 38:448-57. 2004
    ..Drug therapies that have been shown to be beneficial in other forms of lipodystrophy and are currently being evaluated in HIV-associated lipodystrophy are also discussed...
  32. ncbi Avoiding and treating dermal filler complications
    Gottfried Lemperle
    Division of Plastic Surgery, University of California, USA
    Plast Reconstr Surg 118:92S-107S. 2006
    ..Surgical excisions shall remain the last option and are indicated for hard lumps in the lips and visible hard nodules or hard granuloma in the subcutaneous fat...
  33. ncbi Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART
    Giovanni Guaraldi
    Department of Medical and Surgery Specialities, Infectious Diseases Clinic, University of Modena and Reggio Emilia School of Medicine, Italy
    HIV Clin Trials 4:99-106. 2003
    ..To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-infected patients on HAART...
  34. ncbi The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth, 6000, Western Australia
    J HIV Ther 9:34-40. 2004
    ..Implications for clinical assessment and management are also considered, within a broader contest that incorporates treatment efficacy as well as toxicity...
  35. ncbi Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens
    Simon P Jones
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 40:565-72. 2005
    ....
  36. ncbi Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz
    Alessandro Viganò
    Department of Paediatrics, L Sacco Hospital, University of Milan, Italy
    Antivir Ther 12:297-302. 2007
    ..We assess the effect on body composition parameters of replacing stavudine with tenofovir and protease inhibitor with efavirenz in paediatric patients...
  37. ncbi Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy
    Julian Falutz
    Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada
    Nat Clin Pract Endocrinol Metab 3:651-61. 2007
    ..Individualized approaches, taking into consideration quality-of-life issues, and assessment of potential cardiovascular risks, are now an important component of effective care of HIV-infected patients...
  38. ncbi Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population
    A B Hansen
    Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
    HIV Med 7:38-45. 2006
    ..To establish the prevalence and quantify the severity of body fat redistribution and dyslipidaemia in HIV-infected men after long-term highly active antiretroviral therapy (HAART) compared with the background population...
  39. ncbi [Lipid disorders in patients with HIV-induced diseases]
    B Chanu
    Service d endocrinologie, de diabétologie et de nutrition, Hopital Jean Verdier, Bondy 93
    Presse Med 34:1087-94. 2005
    ..Management of these metabolic disorders is based primarily on a change in the drug regimen (administration of the least deleterious combinations), followed by standard dietary measures and, when necessary, lipid-lowering agents...
  40. ncbi Antiretroviral-therapy-associated lipoatrophy: current status and future directions
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Australia
    Sex Health 2:153-63. 2005
    ....
  41. ncbi Cervical lipomatosis in HIV-infected patients: a case-control study
    R Palacios
    Infectious Diseases Unit, Hosp Virgen de la Victoria, 29010 Malaga, Spain
    HIV Med 8:17-21. 2007
    ..The aim of the study was to analyse the prevalence of cervical lipomatosis (CL) in HIV-infected patients on highly active antiretroviral therapy (HAART) and the factors associated with its development...
  42. ncbi Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
    R A Bradbury
    Diabetes and Obesity Clinical Group, Diabetes Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010, Australia
    Diabetes Obes Metab 10:441-50. 2008
    ..These complications are likely to contribute to an increased risk of premature and accelerated atherosclerosis with growing concern about potential cardiovascular consequences...
  43. ncbi Hyperproinsulinaemia in normoglycaemic lipodystrophic HIV-infected patients
    S B Haugaard
    Department of Endocrinology and Internal Medicine, Hvidovre University Hospital, Copenhagen, Denmark
    Eur J Clin Invest 36:436-45. 2006
    ....
  44. ncbi Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry
    Neda Tavassoli
    Service de Pharmacologie Clinique, Cent re Midi Pyrénées de Pharmacovigilance, de Pharmacoepidemiologie et d Informations sur le Medicament, Faculte de Medecine, Hopitaux de Toulouse, Toulouse, France
    Pharmacotherapy 26:154-61. 2006
    ..To determine whether discontinuation of stavudine or protease inhibitor therapy improves human immunodeficiency virus (HIV)-related fat distribution in men...
  45. ncbi Disorders of glucose metabolism in the context of human immunodeficiency virus infection
    Ruth Larson
    Internal Medicine, Niagara Falls Memorial Medical Center, Lewiston, NY 14092, USA
    J Am Acad Nurse Pract 18:92-103. 2006
    ..To discuss the pathophysiology and the current treatment approaches for the dysregulation of glucose metabolism in the context of human immunodeficiency virus (HIV) infection...
  46. ncbi Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy
    Donald P Kolter
    Gastrointestinal Division, St Luke s Roosevelt Hospital Center, New York, USA
    AIDS Read 13:S5-13. 2003
    ..While many of the treatments for the broad range of signs and symptoms of lipodystrophy bring about improvements in patient status, none have been demonstrated to bring about a return to baseline levels...
  47. ncbi Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
    ..To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia...
  48. ncbi A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load
    J A Arranz Caso
    Infectious Diseases Unit, Hospital Principe de Asturias, Madrid, Spain
    HIV Med 6:353-9. 2005
    ..To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment...
  49. ncbi The clinical implications of antiretroviral pharmacogenomics
    Julie Fox
    St Mary s Hospital, Clinical Trials Centre, Winston Churchill Wing, Division of Medicine, Imperial College London, Praed Street, London W2 1NY, UK
    Pharmacogenomics 7:587-96. 2006
    ..This review summarizes the key findings in the growing knowledge between human genetics and response to antiretroviral drugs and how these findings may be effectively applied in a clinical context...
  50. ncbi [Toxic epidermal necrolysis associated with abacavir]
    Milagro Montero
    Enferm Infecc Microbiol Clin 23:247. 2005
  51. ncbi Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
    Jim Young
    Institut für Klinische Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:73-81. 2005
    ..Our objective is to show whether such associations are more or less likely for patients on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART...
  52. ncbi The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients
    Ei Ei Tin
    Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 36:362-9. 2005
    ..043). GPO-VIR is an inexpensive and effective antiretroviral drug regimen for initiating treatment of naïve patients, but careful assessment for lipodystrophy is necessary, especially after one year of treatment...
  53. ncbi Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy
    Steen B Haugaard
    Clinical Research Unit, Hvidovre University Hospital, University of Copenhagen, Denmark
    Clin Endocrinol (Oxf) 62:354-61. 2005
    ....
  54. ncbi High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
    Trans R Soc Trop Med Hyg 101:793-8. 2007
    ..Lipoatrophy appears to be an important long-term complication of WHO-recommended first-line ART regimens. These data highlight the urgent need for access to more affordable and less toxic ART regimens in resource-limited settings...
  55. ncbi Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men
    Todd Brown
    Johns Hopkins University, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:356-62. 2006
    ....
  56. ncbi Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy
    Victor Asensi
    Infectious Diseases Unit, Hospital Central de Asturias, Oviedo University School of Medicine, Celestino Villamil s n, 33004 Oviedo, Spain
    Clin Infect Dis 39:240-7. 2004
    ..Echographically measured PRFD is associated with lipodystrophy and could be used as an early predictor of this syndrome in treatment-naive patients starting HAART...
  57. ncbi Body shape and composition in HIV-infected women: an urban cohort
    S L Karmon
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    HIV Med 6:245-52. 2005
    ..In this study, we sought to characterize the body changes reported by women attending a US urban clinic, and to evaluate contributing factors using inexpensive methods that are readily available in clinical practice...
  58. ncbi Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy
    Angel Moreno-Torres
    Research Department, Centre Diagnostic Pedralbes, Esplugues de Llobregat, Spain
    Antivir Ther 12:195-203. 2007
    ....
  59. pmc The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study
    Joan C Lo
    Div of Endocrinology, General Clinical Research Center at San Francisco General Hospital, San Francisco, California 94110, USA
    Clin Infect Dis 39:732-5. 2004
    ..Visceral adipose tissue (VAT) levels did not change significantly for the group as a whole, although a reduction in the VAT level was seen in patients with a greater VAT level at baseline...
  60. ncbi Toxic metabolic syndrome associated with HAART
    Steen B Haugaard
    Clinical Research Unit, Department of Endocrinology and Internal Medicine, Hvidovre University Hospital, DK 2650 Hvidovre, Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 2:429-45. 2006
    ..An opinion on the remedies available to treat the metabolic abnormalities and phenotype of HALS is provided...
  61. ncbi Metabolic complications of HIV therapy in children
    Grace A McComsey
    AIDS 18:1753-68. 2004
  62. ncbi [Effect of anti-retroviral therapy on body composition changes: a literature review]
    C Dell'Isola
    VIII Divisione Dipartimento Urgenze Infettivologiche ad Alta Complessita, A O D Cotugno, Napoli, Italy
    Infez Med 14:5-12. 2006
    ..Most of the medical therapies proposed for lipodystrophy are ineffective, and even if surgery remains an alternative, it is not associated with long lasting outcomes...
  63. ncbi [Factors predicting the failure of interruption of highly active antiretroviral treatment (HAART) in HIV-infected patients]
    Miguel Cervero-Jiménez
    Servicio de Medicina Interna, Hospital Severo Ochoa, Leganes, Madrid, Espana
    Enferm Infecc Microbiol Clin 23:202-7. 2005
    ..Treatment interruptions may be an alternative to HAART in the management of chronically infected HIV-patients. We designed this study in an attempt to assess the predictability of this strategy...
  64. ncbi Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy
    Ksenia Sevastianova
    Minerva Institute for Medical Research, Helsinki, Finland
    Am J Physiol Endocrinol Metab 295:E85-91. 2008
    ..CD68, ITGAM, CCL2, and CCL3 expression is significantly associated with accumulation of liver fat...
  65. ncbi Fat distribution in relation to drug use, human immunodeficiency virus (HIV) status, and the use of antiretroviral therapies in Hispanic patients with HIV infection
    J E Forrester
    Department of Family Medicine and Community Health, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Clin Infect Dis 37:S62-8. 2003
    ..The role of patient-specific factors in the etiology of HIV-associated fat-redistribution syndrome warrants further investigation...
  66. ncbi Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study
    Alain Lafeuillade
    Department of Infectious Diseases, Chalucet Hospital, Toulon, France
    HIV Clin Trials 4:37-43. 2003
    ..To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks...
  67. ncbi Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy
    Julian Deonarain
    Department of Anatomical Pathology, University of KwaZulu Natal, National Health Laboratory Service Durban, South Africa
    Int J Surg Pathol 16:171-5. 2008
    ....
  68. ncbi Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor
    Pere Domingo
    Department of Internal Medicine Infectious Diseases Unit Biochemistry and Endocrinology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Antivir Ther 8:223-31. 2003
    ....
  69. ncbi Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy
    Regje Me Blümer
    Department of Endocrinology and Metabolism, The Netherlands
    AIDS 22:227-36. 2008
    ..It is not known whether changes in body composition are necessary for the development of these disturbances in ART-naive patients starting treatment with different combination ART regimens...
  70. ncbi Endothelial markers and HIV infection in the era of highly active antiretroviral treatment
    Gabriela F de Larrañaga
    Haemostasis and Thrombosis Lab, Argentinian Group of AIDS Researchers GADIS, Infectious Diseases Hospital, F J Muniz, Uspallata 2272, C1282AEN, Buenos Aires, Argentina
    Thromb Res 110:93-8. 2003
    ....
  71. ncbi Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen
    Reshma S Autar
    The HIV Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 12:1265-71. 2007
    ..The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood...
  72. ncbi Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children
    Alessandra Vigano
    Department of Pediatrics, L Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    J Acquir Immune Defic Syndr 32:482-9. 2003
    ..To assess body composition changes in HIV-infected children receiving highly active antiretroviral therapy (HAART)...
  73. ncbi Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies
    M K S Leow
    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 88:1961-76. 2003
  74. ncbi The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes
    Maria Saumoy
    Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain
    AIDS 22:893-6. 2008
    ..The IL-6 -174 G>C genotype distribution and allele frequencies, SAT IL-6 mRNA expression and IL-6 plasma levels were non-significantly different between HIV-1-infected patients with and without lipodystrophy...
  75. ncbi HIV-associated facial lipoatrophy
    Julia James
    Division of Dermatology and Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada
    Dermatol Surg 28:979-86. 2002
    ..HIV-infected individuals are living long, healthy lives. They are now concerned with less life-threatening problems, especially lipodystrophy...
  76. ncbi Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy
    Grace McComsey
    Center for AIDS Research, Case Western Reserve University, Cleveland, Ohio, USA
    AIDS Read 13:539-42, 559. 2003
    ..Our results emphasize the need for keeping in mind the role of host factors in the generation of lipoatrophy...
  77. ncbi Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 2007
    Ann Nestorowicz
    International Medical Press Ltd, Sydney, NSW, Australia
    Antivir Ther 12:987-98. 2007
    ..Finally, advances in the development of pharmacovigilance reporting systems in resource-limited settings and their impact upon healthcare policies and the provision of patient care were also described...
  78. ncbi Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients
    Eric Bonnet
    INSERM U563, Centre de Physiopathologie de Toulouse Purpan, and Université Toulouse III Paul Sabatier, IFR30, Toulouse, F 31300, France
    AIDS Res Hum Retroviruses 24:169-71. 2008
    ..2 vs. 66.5 mg/liter) and a lower fat mass (13.9 vs. 19.7%) than patients with nonvariant alleles (-455 0/-482 0). APOC3 polymorphisms might be associated with both dyslipidemia and lipoatrophy in HAART-treated patients...
  79. ncbi Reviving protease inhibitors: new data and more options
    Robert L Murphy
    The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Acquir Immune Defic Syndr 33:S43-52; quiz S53, S55-6. 2003
  80. ncbi High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution
    W Jeffrey Fessel
    Kaiser Perminente Medical Care Program, San Francisco, California 94115, USA
    AIDS 16:1785-9. 2002
    ..To demonstrate relationships between plasma high-density lipoprotein (HDL) cholesterol and fat expansions in the fat redistribution syndrome...
  81. ncbi Simplified regimens for treating HIV infection and AIDS
    Peter J Piliero
    Division of Clinical Pharmacology, Albany Medical College, Albany, New York, USA
    J Am Acad Nurse Pract 15:305-12. 2003
    ..To review the variables that greatly affect adherence to the complex treatment regimens used in HIV disease and to examine available options that could improve patient outcomes...
  82. ncbi Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings
    Alain Makinson
    University Hospital, Department of Infectious and Tropical Diseases, Montpellier, France
    Expert Opin Drug Saf 7:283-93. 2008
    ..Yet it remains a cornerstone of treatment in resource-limited settings, due to lack of alternatives and its availability in generic fixed-dose combinations...
  83. ncbi Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES)
    Selwyn H Lowe
    International Antiviral Therapy Evaluation Center IATEC, Amsterdam, The Netherlands
    HIV Clin Trials 8:337-44. 2007
    ....
  84. ncbi Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
    L Ruiz
    IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 27:229-36. 2001
    ..Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy...
  85. pmc Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome
    Dominic C Chow
    Hawaii AIDS Clinical Research Program, University of Hawaii, Honolulu, HI, USA
    Biologics 2:917-21. 2008
    ..Niacin is thought to affect hormone-sensitive lipase (HSL) and lipoprotein lipase (LPL) expression in peripheral and intra-abdominal fat (IAF)...
  86. ncbi Role of interleukin-18 in the development and pathogenesis of AIDS
    Alexandre Iannello
    Laboratory of Innate Immunity, CHU Sainte Justine Research Center, University of Montreal, Montreal, Quebec, Canada
    AIDS Rev 11:115-25. 2009
    ..It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein...
  87. pmc Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy
    Shashi Shrivastav
    Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Disease NIH, 10 Center Drive MSC 1268, Bethesda, MD 20892 1268, USA
    Mol Endocrinol 22:234-47. 2008
    ..Vpr may alter sensitivity to insulin and thereby contribute to the development of lipodystrophy and insulin resistance observed in HIV-1-infected patients...
  88. ncbi [Metabolic syndrome and hyperlipidemia in HIV-positive patients]
    Georg M N Behrens
    Abteilung Klinische Immunologie, Medizinische Hochschule, Hannover
    Herz 30:458-66. 2005
    ....
  89. ncbi Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome
    Giuseppe Barbaro
    Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Curr Pharm Des 13:2208-13. 2007
    ....
  90. ncbi HIV lipodystrophy: prevalence, severity and correlates of risk in Australia
    J Miller
    The National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 4:293-301. 2003
    ..To establish the prevalence, severity and factors associated with the HIV lipodystrophy syndrome...
  91. ncbi High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy
    Birgitte Lindegaard
    Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark
    J Acquir Immune Defic Syndr 36:588-93. 2004
    ..An inverse correlation was observed between IL-18 and limb fat (P <0.05). In conclusion, the level of IL-18 is elevated in patients with LD and closely linked to limb atrophy, whereas it is not associated with cholesterol or IR...
  92. ncbi Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy
    G M N Behrens
    Immunology Division, The Walter and Eliza Hall Institute of Medical Research, IG Royal Parade, Parkville 3050, Victoria, Australia
    Eur J Med Res 8:221-5. 2003
    ..This results in altered LMNA expression and subsequent impaired adipocyte differentiation, lipodystrophic body habitus, and metabolic disturbances in HIV infected patients receiving HAART...
  93. ncbi The association of lipodystrophy and oxidative stress biomarkers in HIV-infected men
    Helena S Vassimon
    Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
    Curr HIV Res 8:364-9. 2010
    ..73, p < 0.05) and HIV+LIPO- (r = 0.54, p < 0.05) groups. Therefore, higher lipid and protein oxidation were found in HIV-infected patients with lipodystrophy syndrome, and both were associated with insulin levels...
  94. ncbi Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment
    S Mauss
    Centre for HIV and Hepatogastroenterology, Grafenberger Allee, Duesseldorf, Germany
    HIV Med 3:49-55. 2002
    ....
  95. ncbi Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:156-62. 2005
    ....
  96. ncbi Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome
    Martin Torriani
    Division of Musculoskeletal Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Appl Physiol (1985) 95:1005-10. 2003
    ..Further studies are needed to assess the mechanisms and consequences of intramuscular lipid accumulation in HIV-infected patients...
  97. ncbi An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
    A Carr
    HIV, Immunology, and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Lancet 361:726-35. 2003
    ..However, an objective, validated definition of the disorder does not exist. We aimed to develop an objective, sensitive, specific, and broadly applicable case definition of HIV lipodystrophy...
  98. ncbi Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study
    A Schwenk
    Department of Infectious Diseases, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Eur J Med Res 5:443-8. 2000
    ..Risk factors for the HIV-associated lipodystrophy syndrome (HALS) were studied in a single-centre, cross-sectional study. -..
  99. ncbi Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels
    Aina S Lihn
    Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Tage Hansensgade 2, 8000 Aarhus C, Denmark
    Am J Physiol Endocrinol Metab 285:E1072-80. 2003
    ..Increased cytokine mRNA in AT is hypothesized to exert an inhibitory effect on adiponectin gene expression and, consequently, to play a role in the reduced plasma adiponectin levels found in HALS patients...
  100. ncbi HIV and HIV treatment: effects on fats, glucose and lipids
    Effrossyni Gkrania-Klotsas
    Department of Infectious Diseases, Addenbrooke s Hospital, Cambridge University Hospitals NHS Foundation Trust, Box 25, Hills Road, Cambridge CB22QQ, UK
    Br Med Bull 84:49-68. 2007
    ..Other metabolic associations including lactic acidosis, HIV-associated bone disease and the effect of the virus on other endocrine pathways are outside the scope of this article...
  101. ncbi Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART)
    François Jérome Authier
    Hopital Henri Mondor, Departement de Pathologie, Creteil F 94010, France
    Muscle Nerve 32:247-60. 2005
    ....

Research Grants52

  1. MOLECULAR BASIS OF HIV LIPODYSTROPHY: ROLE OF VPR
    Ashok Balasubramanyam; Fiscal Year: 2003
    ....
  2. Can IGF-I/IGFBP-3 Reverse Central Fat Accumulation?
    Morris Schambelan; Fiscal Year: 2005
    ..Should the results of this preliminary study be positive, they would provide a rationale for further studies of this agent, including a randomized, double-blind, placebo-controlled trial. ..
  3. Is HIV-associated lipodystrophy a risk factor for cirrhosis of the liver?
    George Ioannou; Fiscal Year: 2013
    ..5. Ultimately, help reduce the burden of cirrhosis which is the second leading cause of death in HIV-infected persons. ..
  4. Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
    Roy J Kim; Fiscal Year: 2011
    ..The purpose of this study is to test the efficacy of recombinant IGF-I in the treatment of HIV associated lipodystrophy syndrome. The specific aims are to (1) Determine the effect of recombinant IGF-I on subcutaneous adiposity ..
  5. HIV associated Lipodystrophy Syndrome in Children: Role of nutrition, ART &Genes
    Soumya Swaminathan; Fiscal Year: 2013
    ..The study has implications for ART programs in India and other resource-constrained countries that are using Stavudine in the first-line ART regimen for children. ..
  6. BODY COMPOSITION: METHODS, MODEL & CLINICAL APPLICATION
    Dympna Gallagher; Fiscal Year: 2005
    ..abstract_text> ..
  7. The effects of HIV-1 proteins on adipocyte biology
    Lisa Kosmiski; Fiscal Year: 2005
    ..These novel studies should provide further insight into the pathogenesis of the body fat changes associated with the HIV lipodystrophy syndrome. ..
  8. Leptin Treatment of HIV-Associated Lipodystrophy
    Morris Schambelan; Fiscal Year: 2004
    ..To evaluate the effects of leptin on whole-body and regional fat and lean tissue distribution, we will also perform whole-body dual-energy X-ray (DEXA) scanning. ..
  9. Mechanisms of Atherosclerosis and CVD in HIV+ Women
    Robert Kaplan; Fiscal Year: 2009
    ..This investigation will have major implications for the development of strategies to predict, prevent, or reverse atherosclerosis in HIV- infected women. ..
  10. PROTEASE INHIBITOR RELATED ATHEROSCLEROSIS IN HIV
    Andrew Carr; Fiscal Year: 2005
    ....
  11. Role of Mitochondria in HIV Lipoatrophy
    Grace McComsey; Fiscal Year: 2009
    ..abstract_text> ..
  12. Uridine Supplementation for HIV lipoatrophy
    Grace McComsey; Fiscal Year: 2007
    ..On-study subjects will continue to be followed per study protocol for a total of 12 months. The last 6 months of the grant will be dedicated to processing of samples and analysis of all data. [unreadable] [unreadable]..
  13. Metabolic Consequences of Thymidine Sparing Regimens
    Grace A McComsey; Fiscal Year: 2010
    ..at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..
  14. Mitochondria And Metabolic Complications Of HIV
    Pablo Tebas; Fiscal Year: 2006
    ..In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies. ..
  15. AIDS CLINICAL TRIALS UNIT
    Pablo Tebas; Fiscal Year: 2007
    ..The investigators have credentials in basic and patient-oriented clinical research. ..
  16. Androgen Effects in HIV-Infected Women
    Steven Grinspoon; Fiscal Year: 2007
    ..The studies outlined in this renewal constitute an important investigative initiative of a targeted, gender-specific therapy in this largely understudied population. ..
  17. HIV+ Prison Releases to Access to HIV Care and Services
    David Wohl; Fiscal Year: 2007
    ..2. BCM will reduce intimate and drug related HIV transmission risk behaviors during the year following prison release. ..
  18. Incarceration and HIV-Infected Inmates
    David A Wohl; Fiscal Year: 2010
    ..Aim 2. Determine the inmate, nurse-counselor and facility characteristics associated with agreeing to HIV VCT. Aim 3. Explore the risks associated with receiving an HIV diagnosis in prison. ..
  19. Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome
    STEVEN KYLE GRINSPOON; Fiscal Year: 2010
    ..Lay Description: This grant will study how commonly low GH level are seen and contribute to increased cardiac risk in patients with abdominal fat and whether increasing low GH levels will improve cardiac risk in this population. ..
  20. Anti-lipolytic Therapy for HIV Lipodystrophy
    Colleen Hadigan; Fiscal Year: 2003
    ..Together, these data will be used to develop future long-term studies to evaluate the efficacy and safety of anti-lipolytic strategies in HIV infected patients with HAART-associated metabolic abnormalities and fat redistribution. ..
  21. MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS
    Steven Grinspoon; Fiscal Year: 2004
    ..The proposed studies represent a significant collaborative effort between clinical researchers, adipocyte biologists, epidemiologists and nutritional biochemists in satisfaction of the mandate of the RFA. ..
  22. INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME
    Colleen Hadigan; Fiscal Year: 2004
    ....
  23. Lipodystrophy among HIV-infected patients
    Heidi Crane; Fiscal Year: 2008
    ..abstract_text> ..
  24. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..
  25. MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEA
    Christine Wanke; Fiscal Year: 2007
    ..In addition, this award will support my ability to mentor trainees in these important clinical research questions. [unreadable] [unreadable]..
  26. Bone mass and mineral metabolism in HIV+ women
    Michael Yin; Fiscal Year: 2008
    ..abstract_text> ..
  27. Phase II study of cholic acid for hepatic steatosis in *
    Abhimanyu Garg; Fiscal Year: 2008
    ..The effectiveness of cholic acid in reducing hepatic steatosis in humans remains unknown. [unreadable] [unreadable]..
  28. Lipoprotein Metabolism 2008 Gordon Research Conference
    Robert Hegele; Fiscal Year: 2008
    ..End of Abstract) [unreadable] [unreadable] [unreadable]..
  29. T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPY
    Marc Hellerstein; Fiscal Year: 2002
    ....
  30. MECHANISMS OF LIPODYSTROPHY IN HIV INFECTED PATIENTS
    Abhimanyu Garg; Fiscal Year: 2002
    ..Additionally, the study may prove effectiveness and reduced toxicity of alternative antiretroviral regimens without a PI. ..
  31. Micronutrient Metabolism in HIV+and HIV-Drug Users
    Janet Forrester; Fiscal Year: 2004
    ..The long term goal of this research is to develop effective interventions to improve the nutritional status and health outcomes of drug abusers with and without infectious diseases, including HIV. ..
  32. Role of macrophages in HIV Lipoatrophy
    Cecilia M Shikuma; Fiscal Year: 2010
    ..We are particularly well suited to undertake these studies as our research team combines clinical research expertise in HIV lipoatrophy with specific laboratory competency in adipose tissue-, mitochondrial- and M/MO-related research. ..
  33. Mentored Patient-Oriented Research Career Development Award
    Martin Torriani; Fiscal Year: 2008
    ..abstract_text> ..
  34. Bisphosphonate therapy for HIV-Associated osteopenia
    Jeannie Huang; Fiscal Year: 2005
    ..Finally, data generated by this pilot study will lay the foundation for future studies of bisphosphonate therapy in HIV-infected persons with bone disease. ..
  35. HAWAII ACTU - ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM
    Cecilia Shikuma; Fiscal Year: 2008
    ..abstract_text> ..
  36. Feasibility Study of Probiotics for Growth Faltering
    Christine Wanke; Fiscal Year: 2006
    ..These data will be used, with the feasibility data obtained, to prepare a proposal for a full clinical trial of LGG as an intervention for growth faltering and diarrheal disease at the time of weaning in these children. ..
  37. Bone Marrow Fat and Osteopenia in HIV Lipodystrophy
    Jeannie Huang; Fiscal Year: 2006
    ....
  38. Therapeutic Approaches to HAART-Induced Lipodystrophy
    Abhimanyu Garg; Fiscal Year: 2006
    ..Additionally, the study may help prevent these problems in HIV-infected patients being initiated on PI-containing HAART. ..
  39. FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION
    Carl Grunfeld; Fiscal Year: 2006
    ..The results will provide essential information on the risk of atherosclerosis and its contributors to aid in patient care, policy and future research. [unreadable] [unreadable] [unreadable]..
  40. Mitochondrial Function and HIV Lipoatrophy
    Cecilia Shikuma; Fiscal Year: 2005
    ..Obtained ATP levels will be correlated with level of adipocyte apoptosis as well as with adipocyte mtDNA copies/cell by real-time PCR and SC adipose tissue expression of select oxidative phosphorylation (OXPHOS) genes. ..
  41. Cognitive Consequences of Endocrine Dysfunction in IDU
    Adrian Dobs; Fiscal Year: 2007
    ..We will obtain a better understanding of the relationship between drug use and cognition, and also expand our understanding of the effects of sex steroids on cognitive performance, in an under-studied population. ..
  42. Role of Protein (S14)in Normal and Neoplastic Mammary
    WILLIAM KINLAW; Fiscal Year: 2005
    ..These studies will provide a comprehensive view of the role of this novel nuclear protein in both normal mammary physiology and in breast cancer, and are likely to reveal a new class of therapeutic targets. ..
  43. Nutritional Status In HIV Hispanic Drug Abusers
    Janet Forrester; Fiscal Year: 2008
    ..The proposed study will build on the infrastructure of the BIENESTAR study (NIDA DA 11598) and the BIENESTAR-micronutrient study (NIDA DA 14501). ..
  44. Oxidant Stress and Antioxidants during HIV Therapy
    Todd Hulgan; Fiscal Year: 2007
    ..The candidate's long-term goal is to develop into an independent clinical investigator in this field of study. ..
  45. DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS
    Marc Hellerstein; Fiscal Year: 2004
    ..Results have potential relevance to HIV-1 pathogenesis and therapy and to vaccination strategies. ..
  46. Response to and signals of caloric restriction and intermittent feeding regimens
    MARC KOPEL HELLERSTEIN; Fiscal Year: 2010
    ....
  47. ADIPOCYTE TURNOVER AND METABOLISM IN HIV-1 LIPOATROPHY
    Marc Hellerstein; Fiscal Year: 2003
    ....
  48. Novel Therapies for Metabolic Complications in Patients with Lipodystrophies
    Abhimanyu Garg; Fiscal Year: 2010
    ..Additionally, the findings may be applicable to treating metabolic complications in patients with obesity and type 2 diabetes. ..
  49. GONADAL HORMONES ON BODY COMPOSITION, HIV AND DRUG USE
    Adrian Dobs; Fiscal Year: 2002
    ..These studies can provide information to further our understanding of gender differences in disease progression and treatment. ..
  50. Mitochondrial Genomics and Peripheral Neuropathy during HIV Therapy
    Todd Hulgan; Fiscal Year: 2008
    ..Results from this study will also advance the field of "mitochondrial medicine", having broad application across other scientific disciplines and for other human diseases. [unreadable] [unreadable] [unreadable]..